(Hypo)manic symptom severity

Bipolar adolescents with comorbid anxiety showed no differences in (hypo)manic symptoms during active treatment but diverged during the post-treatment phase, with significantly higher (hypo)manic symp

Effect: decline; F(6,503)=3.38 (anxiety x time interaction)

Bipolar adolescents with comorbid anxiety showed no differences in (hypo)manic symptoms during active treatment but diverged during the post-treatment phase, with significantly higher (hypo)manic symp

Effect: decline; F(6,503)=3.38 (anxiety x time interaction)

Bipolar adolescents with comorbid anxiety showed no differences in (hypo)manic symptoms during active treatment but diverged during the post-treatment phase, with significantly higher (hypo)manic symp

Effect: decline; F(6,503)=3.38 (anxiety x time interaction)

Bipolar adolescents with comorbid anxiety showed no differences in (hypo)manic symptoms during active treatment but diverged during the post-treatment phase, with significantly higher (hypo)manic symp

Effect: decline; F(6,503)=3.38 (anxiety x time interaction)

Bipolar adolescents with comorbid anxiety showed no differences in (hypo)manic symptoms during active treatment but diverged during the post-treatment phase, with significantly higher (hypo)manic symp

Effect: decline; F(6,503)=3.38 (anxiety x time interaction)

Bipolar adolescents with comorbid anxiety showed no differences in (hypo)manic symptoms during active treatment but diverged during the post-treatment phase, with significantly higher (hypo)manic symp

Effect: decline; F(6,503)=3.38 (anxiety x time interaction)

Bipolar adolescents with comorbid anxiety showed no differences in (hypo)manic symptoms during active treatment but diverged during the post-treatment phase, with significantly higher (hypo)manic symp

Effect: decline; F(6,503)=3.38 (anxiety x time interaction)

Bipolar adolescents with comorbid anxiety showed no differences in (hypo)manic symptoms during active treatment but diverged during the post-treatment phase, with significantly higher (hypo)manic symp

Effect: decline; F(6,503)=3.38 (anxiety x time interaction)

Bipolar adolescents with comorbid anxiety showed no differences in (hypo)manic symptoms during active treatment but diverged during the post-treatment phase, with significantly higher (hypo)manic symp

Effect: decline; F(6,503)=3.38 (anxiety x time interaction)

Bipolar adolescents with comorbid anxiety showed no differences in (hypo)manic symptoms during active treatment but diverged during the post-treatment phase, with significantly higher (hypo)manic symp

Effect: decline; F(6,503)=3.38 (anxiety x time interaction)

Bipolar adolescents with comorbid anxiety showed no differences in (hypo)manic symptoms during active treatment but diverged during the post-treatment phase, with significantly higher (hypo)manic symp

Effect: decline; F(6,503)=3.38 (anxiety x time interaction)

Bipolar adolescents with comorbid anxiety showed no differences in (hypo)manic symptoms during active treatment but diverged during the post-treatment phase, with significantly higher (hypo)manic symp

Effect: decline; F(6,503)=3.38 (anxiety x time interaction)

Bipolar adolescents with comorbid anxiety showed no differences in (hypo)manic symptoms during active treatment but diverged during the post-treatment phase, with significantly higher (hypo)manic symp

Effect: decline; F(6,503)=3.38 (anxiety x time interaction)

Bipolar adolescents with comorbid anxiety showed no differences in (hypo)manic symptoms during active treatment but diverged during the post-treatment phase, with significantly higher (hypo)manic symp

Effect: decline; F(6,503)=3.38 (anxiety x time interaction)

Bipolar adolescents with comorbid anxiety showed no differences in (hypo)manic symptoms during active treatment but diverged during the post-treatment phase, with significantly higher (hypo)manic symp

Effect: decline; F(6,503)=3.38 (anxiety x time interaction)

Bipolar adolescents with comorbid anxiety showed no differences in (hypo)manic symptoms during active treatment but diverged during the post-treatment phase, with significantly higher (hypo)manic symp

Effect: decline; F(6,503)=3.38 (anxiety x time interaction)

Bipolar adolescents with comorbid anxiety showed no differences in (hypo)manic symptoms during active treatment but diverged during the post-treatment phase, with significantly higher (hypo)manic symp

Effect: decline; F(6,503)=3.38 (anxiety x time interaction)

Bipolar adolescents with comorbid anxiety showed no differences in (hypo)manic symptoms during active treatment but diverged during the post-treatment phase, with significantly higher (hypo)manic symp

Effect: decline; F(6,503)=3.38 (anxiety x time interaction)

Bipolar adolescents with comorbid anxiety showed no differences in (hypo)manic symptoms during active treatment but diverged during the post-treatment phase, with significantly higher (hypo)manic symp

Effect: decline; F(6,503)=3.38 (anxiety x time interaction)

Bipolar adolescents with comorbid anxiety showed no differences in (hypo)manic symptoms during active treatment but diverged during the post-treatment phase, with significantly higher (hypo)manic symp

Effect: decline; F(6,503)=3.38 (anxiety x time interaction)

Bipolar adolescents with comorbid anxiety showed no differences in (hypo)manic symptoms during active treatment but diverged during the post-treatment phase, with significantly higher (hypo)manic symp

Effect: decline; F(6,503)=3.38 (anxiety x time interaction)

Bipolar adolescents with comorbid anxiety showed no differences in (hypo)manic symptoms during active treatment but diverged during the post-treatment phase, with significantly higher (hypo)manic symp

Effect: decline; F(6,503)=3.38 (anxiety x time interaction)

Bipolar adolescents with comorbid anxiety showed no differences in (hypo)manic symptoms during active treatment but diverged during the post-treatment phase, with significantly higher (hypo)manic symp

Effect: decline; F(6,503)=3.38 (anxiety x time interaction)

Bipolar adolescents with comorbid anxiety showed no differences in (hypo)manic symptoms during active treatment but diverged during the post-treatment phase, with significantly higher (hypo)manic symp

Effect: decline; F(6,503)=3.38 (anxiety x time interaction)

Bipolar adolescents with comorbid anxiety showed no differences in (hypo)manic symptoms during active treatment but diverged during the post-treatment phase, with significantly higher (hypo)manic symp

Effect: decline; F(6,503)=3.38 (anxiety x time interaction)

Bipolar adolescents with comorbid anxiety showed no differences in (hypo)manic symptoms during active treatment but diverged during the post-treatment phase, with significantly higher (hypo)manic symp

Effect: decline; F(6,503)=3.38 (anxiety x time interaction)

Bipolar adolescents with comorbid anxiety showed no differences in (hypo)manic symptoms during active treatment but diverged during the post-treatment phase, with significantly higher (hypo)manic symp

Effect: decline; F(6,503)=3.38 (anxiety x time interaction)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)

Bipolar adolescents with comorbid ADHD who received FFT-A showed an 18% decrease in (hypo)manic symptoms from 9 to 24 months, while those with ADHD who received EC had a 2% increase over the same inte

Effect: improvement; 18% decrease in (hypo)manic symptoms from 9-24 months (FFT-A+ADHD) vs 2% increase (EC+ADHD)